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Prescribing restrictions – a necessary strategy among some European countries to enhance future prescribing efficiency?
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Abstract
Introduction: The increasing incidence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) 
strains of Mycobacterium tuberculosis is hampering efforts to control the global tuberculosis (TB) epidemic. 
Although treatment of drug-susceptible TB is possible in ≥ 95% of disease cases, long (≥ 6 months) duration of 
supervised combination therapy is challenging. Non-adherence to treatment often results in much lower cure 
rates. Treatment of MDR-TB and XDR-TB is far less effective. The aim of this review is to summarize the cur-
rent status of fluoroquinolones in shortening the duration of drug-susceptible pulmonary TB and in improving 
the outcome of MDR-TB/XDR-TB.
Methods: All the relevant articles were identified through a search of PubMed and Scopus databases by using 
search terms like tuberculosis (or M. tuberculosis), fluoroquinolones, drug-susceptible TB, MDR-TB, XDR-TB, 
combination therapy, treatment regimens, treatment duration, drug target and drug resistance. The current 
literature on the role of fluoroquinolones in the treatment of TB was reviewed.
Results: The fluoroquinolones, particularly newer compounds such as levofloxacin, moxifloxacin and gatiflox-
acin, have bactericidal activity against M. tuberculosis, excellent oral bioavailability, favorable safety profile and 
no cross-resistance with other first-line anti-TB drugs. Data from phase II trials of fluoroquinolones-contain-
ing regimens for shortening the duration of treatment for pulmonary TB are encouraging and phase III trials 
are currently underway. The fluoroquinolones are also effective as substitute agents for those individuals who 
are intolerant to first-line drugs. Several studies and clinical trials have also supported the use of fluoroquinolo-
nes in patients with MDR-TB/XDR-TB.
Discussion: The fluoroquinolones-containing regimens are being tested to shorten the duration of treatment 
for pulmonary TB to 4 months. They are also regarded as one of the two cornerstone drugs for the treatment of 
MDR-TB/XDR-TB. However, they are also among the commonly prescribed antibiotics for lower respiratory 
tract infections and are becoming increasingly associated with delayed treatment and resistance in TB. If these 
trends are not reversed soon, we may lose fluoroquinolones as effective anti-TB agents very rapidly.
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Introduction
Despite concerted worldwide efforts, tuberculosis (TB) continues to remain a major public health is-
sue of our times as it contributes considerably to illness and death around the world. Active TB disease 
is caused primarily by the obligate human pathogen Mycobacterium tuberculosis. Currently, the TB 
epidemic is being sustained and fuelled by two major factors: global human immunodeficiency virus 
(HIV) infection and its association with active TB disease and increasing resistance of M. tuberculosis 
strains to the most effective (first-line) anti-TB drugs [1,2]. Other factors contributing to the resur-
gence of active TB disease include inadequate TB control and prevention programs as well as poor case 
detection/cure rates in endemic countries, and disease association with other underlying conditions 
including diabetes [1-3].
Close contact with sputum-positive pulmonary TB patients is mainly responsible for new infections 
in a community. Incidentally, primary infection with M. tuberculosis leads to clinical disease in only 
~10% of exposed individuals while initial growth and multiplication of M. tuberculosis is arrested by 
the protective immune response in the remaining cases. However, pathogen clearance occurs in ~10% 
people while the remaining ~90% individuals succeed in containment of infection only as some bacilli 
escape killing and remain in non-replicating (latent) state in granulomatous lesions [4]. The dormant 
bacilli can resuscitate and cause active TB in the event of disruption of host’s immune response [5]. The 
World Health Organization (WHO) has estimated that 2.2 billion people worldwide are now latently 
infected with M. tuberculosis and 5-10% of the infected individuals will eventually develop active TB 
disease during their life time [5,6]. However, the annual risk of active TB is 5-15% and the lifetime risk 
is ~50% in HIV-seropositive individuals [1,7]. 
Epidemiology of TB and drug-resistant TB
The current estimates of global burden of TB are based on the results of yearly surveys conducted by 
the WHO for the prevalence of infection. In 2009, 9.4 million incident cases of active TB disease and 
1.68 million deaths occurred worldwide [1]. Most of the estimated TB cases in 2009 occurred in Asia 
(55%) followed by Africa (30%) while smaller proportions of cases occurred in Eastern Mediterranean 
region (7%), European region (4%) and the region of the Americas (3%). The highest incidence rate 
(340 per 100,000 population) was recorded for the African region, mainly due to higher prevalence of 
concomitant HIV infection [1]. Pulmonary TB accounted for > 85% of active TB cases in high TB in-
cidence countries while extrapulmonary TB was more common in low TB incidence countries [1,8,9]. 
The WHO has also performed surveys for estimating drug susceptibility testing (DST) data for first-line 
drugs: isoniazid (INH), rifampicin (RMP), ethambutol (EMB) and streptomycin (SM) [2]. Resistance 
to at least one anti-TB drug (defined as “any resistance”) among previously treated TB patients (25.1%) 
was higher than in new TB cases (11.1%). The worldwide average for multidrug-resistance (MDR) 
(defined as infection with M. tuberculosis strains resistant at least to INH and RMP) was also higher in 
previously treated TB cases compared to new cases (11.7% versus 1.6%, respectively). Monoresistance 
to RMP occurs rarely except in individuals co-infected with HIV or with other underlying conditions 
and resistance to RMP is considered a good surrogate marker for infection with MDR strains of M. tu-
berculosis (MDR-TB) [2,10,11]. The highest percentage of MDR-TB cases have been estimated for East-
ern European countries (19.2%) followed by Western Pacific region (7%) and Southeast Asia (4.3%). 
Overall, ~440,000 cases of MDR-TB occurred in 2008, resulting in 150,000 deaths [12]. 
The MDR-TB is a major threat to global public health as it is more difficult to treat than drug-suscepti-
ble TB and often results in relapse or treatment failure [13-16]. It is also a risk factor for the emergence 
of extensively drug-resistant (XDR) TB (defined as infection with MDR-TB strains additionally resist-
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ant to a fluoroquinolone and an injectable anti-TB agent such as kanamycin, amikacin, capreomycin or 
viomycin) [12,17]. The XDR-TB is more difficult to treat than MDR-TB even in developed countries 
and is virtually an untreatable disease in much of the developing world [18-22]. By 2009, the presence 
of XDR-TB has been documented in 58 countries. Nearly 5.4% of all MDR-TB cases were found to 
have XDR-TB in 46 countries while eight countries reported XDR-TB in > 10% of all MDR-TB cases. 
No information on the incidence of XDR-TB is available for several other countries that have a high 
incidence of MDR-TB and many of these countries have reported a high incidence of fluoroquinolone 
resistance among MDR-TB strains, indicating that the worldwide incidence of XDR-TB is likely to 
climb further [12]. 
Fluoroquinolones as anti-TB drugs
Fluoroquinolones (FQs) are broad-spectrum bactericidal antimicrobial agents that are currently being 
used for a variety of bacterial infections including respiratory infections other than TB [23-27]. The 
older FQs, such as ciprofloxacin (CFX) and ofloxacin (OFX), are synthetic derivatives of nalidixic acid 
and are highly effective as antibacterial agents. New generation FQs such as levofloxacin (LFX), two 
8-methoxy-fluoroquinolones (mFQs), moxifloxacin (MFX) and gatifloxacin (GFX), are more potent 
antibacterial agents. These drugs are a relatively recent addition to the armamentarium against M. tu-
berculosis [28-31]. The minimum inhibitory concentration (MIC), recommended daily oral dose, early 
bactericidal activity (EBA, a measure of reduction in viable colony forming units during the first few 
days of therapy), pharmacokinetic and other properties of different FQs are summarized in Table I.
Higher daily oral doses of CFX (1500 mg), OFX (800 mg) and LFX (1000 mg) have also been used 
safely in TB patients with normal renal functions [28,30]. The MIC values for mFQs (MFX and GFX) 



























































Table I. The minimum inhibitory concentration (MIC), recommended oral daily dose, bactericidal 
and pharmacokinetic properties and major drug-related side effects of various fluoroquinolones in 
the treatment of tuberculosis
GI/CNS disturbances = signs and symptoms of disturbance of the gastrointestinal system or central nervous 
system
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 • INH = 0.02-0.04 mg/l; 
 • RMP = 0.2-0.4 mg/l; 
 • EMB = 0.5-2.0 mg/l;
 • SM = 0.5-2.0 mg/l. 
The EBA (0-2 days) of MFX and GFX and high dose LFX (and to a lesser extent high dose OFX) is close 
to or equal to that of INH (recorded as 0.5-0.6 at oral dose of 300 mg), which is regarded as the most 
effective anti-TB drug in the intensive phase of chemotherapy [32-36]. The CFX is the least effective 
FQ against M. tuberculosis as the EBA of even high dose CFX is quite low (Table I). Thus, high dose 
LFX and normal dose GFX and MFX are bactericidal while even high dose CFX is bacteriostatic for 
M. tuberculosis. 
The potent EBA of MFX and GFX, against M. tuberculosis and once daily oral dosing make these drugs 
highly desirable agents for combination therapy of fully susceptible pulmonary TB (Table II) [34-39]. 
Since RMP was inducted in combination therapy more than forty years ago, these drugs are the first 
new antibiotic class to be considered as first-line agents against active TB disease and are currently be-
ing evaluated for shortening the treatment duration of fully susceptible pulmonary TB. The FQs (MFX 
and GFX as well as high dose OFX and LFX) with the exception of CFX are also useful as second-line 
agents for the treatment of TB patients who are intolerant to some of the first-line drugs as well as for 
the treatment of drug-resistant TB [30,31,37]. Although early studies used OFX for the treatment of 
drug-resistant TB and MDR-TB, more recent studies in developed countries have mainly used high 
dose LFX (even though it is more expensive than OFX), due to bactericidal and better pharmacoki-
netic properties, in therapy regimens for the treatment of MDR-TB patients [30-32,37]. However, due 
to lower cost, OFX is still being used for the treatment of MDR-TB patients in developing countries.
Early studies carried out in murine models of TB suggested that replacement of EMB or INH with 
MFX in first-line treatment for TB has the potential to improve outcome and to shorten therapy to 
four months from the current standard of six months [40,41]. The maximum treatment benefit was 
noted when MFX was used in place of INH in the murine model of TB [40]. The effect of replacement 
of EMB with standard dose of MFX or GFX (each at 400 mg) was evaluated in three separate phase 
II clinical trials in the intensive phase of treatment of sputum smear-positive pulmonary TB patients 
which yielded variable results. The first of these studies, carried out by the TB Trials Consortium, 
reported higher rates of sputum culture conversion at 4 and 6 weeks of therapy but not at week 8 in 
MFX-containing regimen [42]. Another study conducted in Rio de Janeiro, Brazil, also reported higher 
rates of sputum culture conversion beginning at 2 weeks and persisting till week 8 of therapy in MFX-
containing regimen [43]. The third study carried out in Durban, South Africa (OFLUTUB Consortium 
study) also evaluated the replacement of EMB by MFX or GFX (or by OFX at 800 mg) in the intensive 
phase of standard WHO recommended 6-month regimen. This study reported rapid elimination of 
Fluoroquinolone drug
Recommended for TB 
disease status* 
Intended aim
Current stage  
in clinical practice
Ciprofloxacin, CFX Not recommended None Not in use
Ofloxacin, OFX MDR-TB Treatment Phase II
Levofloxacin, LFX MDR-TB Treatment Phase II
Gatifloxacin, GFX FS-PTB Shortening duration Phase III
Moxifloxacin, MFX FS-PTB Shortening duration Phase III
Table II. The current status of various fluoroquinolones in the treatment of tuberculosis patients 
suffering from various forms of the disease
FS-PTB = fully susceptible pulmonary tuberculosis; MDR-TB = multidrug-resistant tuberculosis
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viable bacteria from sputum of pulmonary TB patients when MFX or GFX was substituted for EMB 
while no measurable improvement was noted when EMB was replaced by OFX [44]. 
The effect of replacement of INH with MFX was also evaluated in a phase II double blind, randomized 
controlled trial in the intensive phase of treatment of sputum smear-positive pulmonary TB patients. 
The conversion from positive sputum cultures at initiation of therapy to negative cultures from sputum 
specimens after 8 weeks of therapy occurred in 99 (60.4%) of 164 participants in MFX group versus 90 
(54.9%) of 164 participants in the INH group. The data showed a slight but statistically insignificant 
(p = 0.37) increase in sputum conversion rate in MFX-containing regimen [45]. The FQs (particularly 
older FQs) have generally been regarded as relatively safer drugs that are well tolerated by most indi-
viduals [27,30,46]. During clinical trials of TB patients, nearly similar number of adverse drug events 
(AEDs) have been recorded in the FQ arm compared to the control arms [30,32]. In the clinical trial 
involving replacement of INH with MFX, serious adverse events were recorded in 9 of 214 TB patients 
in the MFX arm compared to 8 of 205 TB patients in the control arm. Serious adverse events related 
to therapy were recorded in 3 TB patients in the MFX arm and in 2 TB patients in the control arm 
[45]. Thus, unlike some FQs (such as grepafloxacin and sparfloxacin) which were withdrawn from the 
market due to QTc interval prolongation, the recommended daily dose (400 mg) of MFX appears to be 
safe in most TB patients. However, FQs (including MFX and GFX) are known to produce cardiac QTc 
interval prolongation in some patients which limits the recommended daily dose (400 mg) of these 
two compounds that can be safely administered during anti-TB treatment [47]. Furthermore, GFX 
is contraindicated in some TB patients as it can cause dysglycemic events, which seem to occur more 
frequently in elderly and/or diabetic subjects [48].
The results of the four phase II trials involving MFX and GFX have shown that replacement of either 
MFX or GFX with EMB or replacement of MFX with INH is at least as efficacious as the standard 
intensive phase of therapy and may even contribute towards more rapid clearing of the infected lungs 
by rapidly dividing tubercle bacilli [42-45]. Both mFQs are now in two separate phase III clinical trials 
for the treatment of adult patients newly diagnosed with drug sensitive, pulmonary TB for investiga-
tion of whether treatment duration can be effectively shortened to 4 months by substitution of GFX 
for EMB or MFX for either EMB or INH [49,50]. The results of these trials will be compared with the 
WHO therapy regimen of 6 months duration with four standard first-line drugs. The advantages of an 
efficacious four-month treatment regimen are obvious. They will greatly reduce the economic burden 
of delivering TB treatment in impoverished countries and improve treatment-completion rates. The 
evolution and spreading of drug resistant and MDR strains of M. tuberculosis will also be reduced 
considerably.
The FQs, particularly new generation FQs such as LFX, MFX and GFX due to their potent bactericidal 
activity and lack of cross-resistance with existing anti-TB drugs, have also been used extensively for 
the treatment of drug-resistant TB and are now regarded as one of the two most important second-line 
agents for the treatment of MDR-TB [22,28,31,36,51,52]. Several studies have shown that inclusion of 
a FQ (particularly mFQs) and an injectable aminoglycoside (kanamycin or amikacin) or cyclic peptide 
(capreomycin and viomycin) in multidrug treatment regimens has the maximum effect for a more 
favorable outcome in the treatment of MDR-TB [12-14,51-54]. This is also apparent from the fact that 
development of resistance of MDR-TB strains to FQs is associated with poor treatment outcome. Ad-
ditional development of resistance of MDR-TB strains to FQs is also one of two key defining conditions 
of XDR-TB [12-14,53-55]. Although initial studies were carried out with OFX-containing regimens, 
some studies and clinical trials involving MDR-TB patients in developed countries have also used LFX 
in treatment regimens. This is due to the fact that high dose LFX is bactericidal while OFX is bacte-
riostatic. More recently, MFX which is also bactericidal at the daily recommended oral dose, has also 
been used for the treatment of MDR-TB patients. A phase III clinical trial to compare the effectiveness 
of LFX and MFX on the culture conversion after three months of treatment among MDR-TB patients 
22 Reviews in Health Care 2012; 3(1) © SEEd All rights reserved
Role of fluoroquinolones in the treatment of tuberculosis
is currently underway [56]. However, OFX continues to be used for the treatment of MDR-TB patients 
due to its lower cost compared to the other two FQs. 
The FQs have also been useful for the treatment of central nervous system infections as favorable drug 
concentrations were achieved in cerebrospinal fluid (CSF) at daily recommended dose (for GFX and 
MFX) or high-dose (for LFX) administration of these agents in several studies [57-59]. Thus, addition 
of a FQ early in the course of therapy is likely to improve outcome in the treatment of tuberculous 
meningitis, particularly when MDR-TB is suspected or confirmed [60,61]. A phase II clinical trial is 
currently underway to evaluate the pharmacokinetics, pharmacodynamics and tolerability of MFX in 
intensive treatment regimens for TB meningitis [62]. The current clinical development status of impor-
tant FQs in the treatment of drug-susceptible pulmonary TB and MDR-TB is summarized in Table II. 
While more potent FQs (MFX and GFX) are being evaluated for shortening the duration of treatment 
of fully susceptible pulmonary TB, OFX and LFX are being used mainly for the treatment of MDR-TB 
patients. Although FQs, particularly new generation mFQs like MFX and GFX, have the potential to 
contribute to chemotherapy of TB, resistance of M. tuberculosis strains to FQs has also been detected in 
nearly all the countries of the world that are endemic for TB [12]. 
Mechanism of action and resistance of 
fluoroquinolones in M. tuberculosis
Resistance of M. tuberculosis to anti-TB (both, first-line and second-line) drugs is caused exclusively 
by chromosomal mutations occurring at a predictable rate in genes encoding drug targets that reduce 
the susceptibility of M. tuberculosis to specific anti-TB drugs [16,63]. Thus, mutations in target genes, 
rpoB, katG, inhA, embB, rpsL, rrs and pncA are the major mechanisms conferring resistance of clinical 
M. tuberculosis strains to first-line anti-TB drugs RMP, INH, INH, EMB, SM, SM and PZA, respectively 
[16,64-79]. The cellular target of FQs in M. tuberculosis is DNA gyrase, a type II topoisomerase that 
controls negative supercoiling in bacterial DNA. Only one type II topoisomerase activity is present in 
M. tuberculosis, which is also the main target for FQ activity in this organism. The active enzyme is a 
tetramer, consisting of two A and two B subunits that are encoded by gyrA and gyrB genes, respectively. 
Studies have shown that inhibition of DNA gyrase activity by FQs results in inhibition of DNA rep-
lication, transcription and repair, causing cell death [37,80-82]. Clinical M. tuberculosis isolates with 
wild-type gyrA and gyrB gene sequences are highly susceptible to FQs while chromosomal mutations 
in clinical M. tuberculosis strains in gyrA and gyrB genes usually confer moderate to high-level resist-
ance to FQs [37,65,83-85]. In some M. tuberculosis strains, changes in the drug efflux pump systems 
may also result in low-level resistance to FQs [86].
Early in vitro studies, performed with laboratory strains of virulent M. tuberculosis and Mycobacterium 
smegmatis (a non-pathogenic species) showed that resistance to FQs results from missense mutations 
causing amino acid alterations in the conserved and putative FQ binding region in gyrA or gyrB genes 
[85,87]. The presence of missense mutations in the so-called quinolone resistance-determining region 
(QRDR) of gyrA or gyrB genes conferring resistance to FQs was subsequently confirmed by using 
clinical M. tuberculosis isolates in multiple studies [83-85,87-97]. The presence of S95 or T95 at gyrA 
codon 95 is a naturally occurring polymorphism that is not associated with resistance of M. tuberculosis 
isolates to FQs. However, this polymorphism together with katG codon 463 polymorphism (R463 or 
L463), is used to define the three principal genetic groups of worldwide collection of M. tuberculosis 
strains [98-100]. The FQ-resistant clinical M. tuberculosis isolates more frequently contain mutations 
in gyrA gene, particularly at codon 90 (A90) or codon 94 (D94) but also occasionally at codon 74 
(A74), codon 88 (G88) and codon 91 (S91) while mutations in few codons of the gyrB gene occur in a 
small minority of clinical strains [83,89-91]. Surprisingly, some M. tuberculosis isolates have also been 
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described that are hypersusceptible to FQs due to mutations at gyrA codon 80 (T80), particularly in as-
sociation with other FQ resistance-associated mutations [83]. Recent studies have shown that the vast 
majority (~90%) of FQ-resistant M. tuberculosis strains can be accurately detected by analysis of QRDR 
of gyrA gene alone since additional targeting of gyrB gene did not enhance the sensitivity significantly 
[91,93-95]. Attempts have also been made to correlate the nature and kind of gyrA mutations with the 
level of resistance to FQs in M. tuberculosis strains with conflicting results. Some studies have reported 
that M. tuberculosis strains containing D94G mutation in the gyrA gene exhibit high-level resistance to 
FQs while those with D94A mutation have lower MIC for LFX [93,96,97]. On the contrary, other re-
ports have not found an association of different mutation patterns in gyrA or gyrB genes with the level 
of FQ resistance in M. tuberculosis isolates [89,94].
Several genotypic tests have recently been developed (Table III) for rapid (within 1-2 days) detection of 
vast majority of FQ-resistant clinical M. tuberculosis isolates [95]. Although some of these assays target 
both gyrA and gyrB genes, the majority of genotypic tests target only QRDR of gyrA gene for simplicity 
and acceptable levels of sensitivity. The genotypic tests that have been developed include PCR-DNA 
sequencing [83-85], PCR-single strand conformation polymorphism [101], temperature-mediated 
heteroduplex analysis by using denaturing high-pressure liquid chromatography (HPLC) [102], py-
rosequencing [103], microchip array [104], locked nucleic acid probe real-time PCR [105], multiplex 
PCR amplimer conformation analysis [89] and both, in-house developed as well as commercially avail-
able line probe assays [92,96,97].
The FQs are an important component of the therapy regimens for patients with MDR-TB or XDR-TB 
since their inclusion greatly improves treatment outcome. Furthermore, resistance of MDR-TB or XDR-
TB strains to FQs has been shown to increase the risk of treatment failure and death [15,18,53,55,106]. 
Although all FQs share the same drug targets (gyrA and gyrB) and cross-resistance between different 
FQs is generally assumed, there are some reports contrary to these generalizations. A study from Hong 
Kong showed that LFX was effective against some OFX-resistant M. tuberculosis strains [107]. Fur-
thermore, one M. tuberculosis strain resistant to both MFX and GFX with mutation at gyrB codon 533 
(N533T) has also been isolated recently that exhibited in vitro susceptibility to OFX [91]. These find-
ings suggest that cross-resistance between different FQs is not always complete. Nonetheless, resistance 
of M. tuberculosis strains to FQs, including third-generation compounds (MFX and GFX), has been 
described from several countries worldwide [2,12,84]. Recent WHO reports suggest that nearly 25% of 
MDR-TB strains from China and India, the two countries accounting for nearly 35% of all estimated 
Genotypic method Target gene(s)
Turn around time 
(days)
% of FQ-resistant 
strains detected
Selected reference(s)
PCR-DNA sequencing gyrA + gyrB 1-2 43-96 86,96-98
HDA by d-HPLC gyrA 1-2 100 103
Pyrosequencing gyrA 1-2 70 104
Microchip array gyrA 1 92 105
LNAP-rtPCR gyrA 1 71 106
mPCR-ACA gyrA 1-2 58 192
Line probe assays gyrA 1-2 89-100 95,99,100
Table III. Performance of various genotypic methods for rapid detection of fluoroquinolone-
resistant strains of M. tuberculosis
d-HPLC = denaturing high-pressure liquid chromatography; HDA = heteroduplex analysis;  
LNAP-rtPCR, = locked nucleic acid probe-real-time PCR; mPCR-ACA = multiplex PCR-amplimer conformation 
analysis; SSCP = single strand conformation polymorphism
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active TB disease cases and 50% of estimated MDR-TB cases worldwide, are likely to be resistant to 
FQs [1,12]. Several other high TB incidence countries are also predicted to have a high prevalence of 
FQ resistance among MDR-TB strains [12]. Furthermore, the incidence of resistance of M. tuberculosis 
strains to FQs also appears to be increasing in several developing countries [108-111].
How we are creating FQ-resistant TB
The history of treatment of active TB disease during early days of chemotherapy has shown that re-
sistance to anti-TB drugs develops soon after they are introduced into therapy regimens. This is ex-
emplified by development of resistance of M. tuberculosis to SM which developed soon after the drug 
was used as monotherapy in the 1940s [112]. Although para-aminosalicylic acid (PAS) and INH were 
subsequently introduced into combination therapy to suppress the development of resistance to SM, 
resistance to both SM and INH soon became widespread and a challenge to combination therapy. It 
was only when RMP and pyrazinamide (PZA) were introduced into combination therapy and the 
duration was reduced to six months that the problem of drug resistance was brought under control 
[113,114]. However, widespread use and misuse (due to poor quality of medications, non-adherence 
of TB patients to treatment, etc.) of short-course regimens have also resulted in the emergence and 
spreading of MDR-TB strains in the 1980s.
Today, a major impediment in the effective use of FQs in the treatment of both drug-susceptible TB and 
MDR-TB is rapidly emerging due to pre-existing and/or increasing levels of FQ resistance among M. 
tuberculosis strains in several countries. Although FQ-resistant TB is mainly generated by the use of 
these drugs in anti-TB treatment regimens, these agents are also being used widely in the treatment of 
other infections including acute lower respiratory tract infections. This is further complicated by easy, 
uncontrolled access of these drugs in many developing countries. Furthermore, the published expert 
recommendations and clinical guidelines in some countries have promoted widespread use of FQs for 
common infections such as pneumonia and sinusitis. For example, the consensus guidelines of the 
Infectious Disease Society of America (IDSA)/American Thoracic Society (ATS) have recommended 
empiric therapy with a FQ for the management of community-acquired pneumonia as a first-line selec-
tion in several clinical situations, including those with comorbid conditions like renal disease, diabetes 
or immunosuppression [115]. Incidentally, most of these conditions also increase the risk of develop-
ing active TB disease in an individual. Thus, 
such clinical practices are likely to contribute to 
the emergence of FQ resistance in M. tuberculo-
sis. The same conclusions were also advocated 
by a recent study from the United States. This 
study showed that the risk of FQ-resistant TB 
was higher in patients who had received FQs for 
more than 10 days for lower respiratory tract 
infections, particularly if the drug was pre-
scribed 60 days or earlier but before the diagno-
sis of active TB disease [116]. A more recent 
systematic review and meta-analysis has also 
shown that empirical treatment of pneumonia 
with FQs was associated with longer delays in 
diagnosis and treatment of pulmonary TB and a 
higher risk of developing FQ-resistant TB [117]. 
The empirical FQ prescriptions are certainly 
more problematic in developing countries with a high TB incidence since patients diagnosed with 
lower respiratory tract infections in such settings may, in fact, have a much higher chance of active TB 
disease than in low TB incidence developed countries and the diagnosis of their active disease may be 
substantially delayed by monotherapy with FQs. Thus, if we plan to protect FQs for the treatment of TB, 
great caution is warranted while considering the use of FQs in the community setting and to limit/
avoid the use of prolonged or repeated courses of FQs in patients who may be at higher risk of having 
active TB disease.
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Questions for further research
The effectiveness of FQs in the treatment 
of various forms of TB needs further eva-
luation and validation. Two phase III clinical 
trials are currently underway to evaluate the 
effectiveness of a 4-month therapy regimen 
for the treatment of pulmonary TB involving 
substitution of GFX for EMB or MFX for ei-
ther EMB or INH. A phase III trial to com-
pare the effectiveness of LFX and MFX on 
the culture conversion after three months of 
treatment among MDR-TB patients is also 
being carried out presently. A phase II clini-
cal trial to evaluate MFX in treatment regi-
mens for TB meningitis is also currently un-
derway. 
The review in brief
Clinical question Role of fluoroquinolones in the treatment of tuberculosis
Type of review Narrative review
Search of the 
literature
Relevant articles from PubMed and Scopus, with keywords: tuberculosis (or M. tuberculosis), 
fluoroquinolones, drug-susceptible TB, MDR-TB, XDR-TB, combination therapy, treatment regimens, 
treatment duration, drug target and drug resistance
Conclusions The FQ-containing regimens are being tested to shorten the duration of treatment for pulmonary TB to 
4 months. They are also regarded as one of the two cornerstone drugs for the treatment of MDR-TB
Limitations The FQs are among the most commonly prescribed antibiotics for lower respiratory tract infections and 
are becoming increasingly associated with delayed treatment and resistance in TB. If these trends are 
not reversed soon, we may lose FQs very rapidly
25Reviews in Health Care 2012; 3(1)© SEEd All rights reserved
S. Ahmad, E. MokaddasRole of fluoroquinolones in the treatment of tuberculosis
more problematic in developing countries with a high TB incidence since patients diagnosed with 
lower respiratory tract infections in such settings may, in fact, have a much higher chance of active TB 
disease than in low TB incidence developed countries and the diagnosis of their active disease may be 
substantially delayed by monotherapy with FQs. Thus, if we plan to protect FQs for the treatment of TB, 
great caution is warranted while considering the use of FQs in the community setting and to limit/
avoid the use of prolonged or repeated courses of FQs in patients who may be at higher risk of having 
active TB disease.
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